Auro Laboratories Board of Directors

Get the latest insights into the leadership at Auro Laboratories. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Sharat Deorah Chairman & Managing Director
Mr. Siddhartha Deorah Whole Time Director
Mr. Kiran Suresh Kulkarni Whole Time Director
Mrs. Kavita Vijayakant Sharma Ind. Non-Executive Director
Mr. Vishal Kailashchandra Jhunjhunwala Ind. Non-Executive Director
Mr. Mahendra Kumar Daga Ind. Non-Executive Director

Auro Laboratories Share price

AUROLAB

229.9

4.60 (2.04%)
Last updated on 4 Sep, 2025 | 15:29 IST
BUYSELL
Today's High

233.90

Today's Low

217.60

52 Week Low

170.00

52 Week High

303.00

The current prices are delayed, login to your account for live prices

Auro Laboratories FAQs

The board at Auro Laboratories consists of experienced professionals, including Mr. Sharat Deorah , Mr. Siddhartha Deorah , and others, overseeing the company’s strategic and corporate governance.

Directors at Auro Laboratories are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Sharat Deorah is the current chairman at Auro Laboratories.

Executive directors at Auro Laboratories are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Auro Laboratories adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Auro Laboratories, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.